SynthesisPloS one2019
Diagnostic accuracy and prognostic applications of CYFRA 21-1 in head and neck cancer: A systematic review and meta-analysis.
Synthesis in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Occult squamous cell carcinoma presenting as oligometastatic lymphadenopathy. A systematic review with a case report.Oncology reviews · 2026Pooled it
- The role of squamous cell carcinoma antigen and cytokeratin 19 fragment in predicting the outcome of esophageal cancer patients: insights from a meta-analysis.World journal of surgical oncology · 2025Pooled it
- Baseline and treatment-induced change of salivary CYFRA 21 - 1 as independent predictors of recurrence in oral squamous cell carcinoma.Clinical oral investigations · 2026Article
- Clinical Significance of Cytokeratin 19-Fragments (CYFRA 21-1), Osteopontin (OPN) and Human Epididymis Protein 4 (HE4) in Pancreatic Adenocarcinoma.International journal of molecular sciences · 2026Article
- Longitudinal Analysis of CYFRA 21-1 Levels in Patients with Pulmonary Nodules: Differential Trajectories Between Benign and Malignant Cases and Impact of Tumor Resection.medRxiv : the preprint server for health sciences · 2026Article
- Perspectives on the Application of Biosensors for the Early Detection of Oral Cancer.Sensors (Basel, Switzerland) · 2025Review
- Development of a Clinical Prediction Model to Predict Malignant Transformation of Sinonasal Inverted Papilloma Based on Hematological Indices and Clinical Features.Laryngoscope investigative otolaryngology · 2025Article
- Development of a Prognostic Score in Patients With Advanced Breast Cancer Treated for Meningeal Carcinomatosis.The breast journal · 2025Article
- CLDN18.2: a potential nanotherapeutic target for cholangiocarcinoma.Frontiers in pharmacology · 2025Review
- The Diagnostic Significance of the Tumor Marker CYFRA 21-1 in Patients with Laryngeal Carcinoma.Materia socio-medica · 2025Article
- Article
- Emerging histological and serological biomarkers in oral squamous cell carcinoma: Applications in diagnosis, prognosis evaluation and personalized therapeutics (Review).Oncology reports · 2023Review
- Pleural Mesothelioma: Advances in Blood and Pleural Biomarkers.Journal of clinical medicine · 2023Review
- The Gut Microbiome from a Biomarker to a Novel Therapeutic Strategy for Immunotherapy Response in Patients with Lung Cancer.Current oncology (Toronto, Ont.) · 2023Review
- Liquid Biopsy and Circulating Biomarkers for the Diagnosis of Precancerous and Cancerous Oral Lesions.Non-coding RNA · 2022Review
- Elevated serum CYFRA 21-1 level as a diagnostic marker for thymic carcinoma.Thoracic cancer · 2021Article
- Molecular alterations in oral cancer between tobacco chewers and smokers using serum proteomics.Cancer biomarkers : section A of Disease markers · 2021Article
- CYFRA21-1/TG ratio as an accurate risk factor to predict eye metastasis in nasopharyngeal carcinoma: A STROBE-compliant article.Medicine · 2020Article
- Clinical relevance of CYFRA 21-1 as a tumour marker in patients with oropharyngeal squamous cell carcinoma.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2020Article
- Study on the Salivary Microbial Alteration of Men With Head and Neck Cancer and Its Relationship With Symptoms in Southwest China.Frontiers in cellular and infection microbiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cytokeratin fraction 21-1 (CYFRA 21-1) has been widely studied as an important biomarker in non-small cell lung cancer for both diagnosis and prognosis. Many studies have also assessed the clinical applications of CYFRA 21-1 in head and neck cancer, but the diagnostic and prognostic values of CYFRA 21-1 are not yet fully established. This pooled analysis aims at evaluating the diagnostic accuracy and prognostic applications of CYFRA 21-1 in patients with head and neck cancer. A systematic retrieval of literatures was conducted without time or language restrictions by searching PubMed, EMBASE, Web of Science, Cochrane library and China National Knowledge Infrastructure. Twenty studies were eligible for systematic review, of which 14 conformed for diagnostic analysis and 7 for prognostic analysis. The pooled sensitivity and specificity of CYFRA 21-1 analysis were 0.53 (95% CI: 0.39-0.67) and 0.97 (95% CI: 0.93-0.99), respectively. A high level of CYFRA 21-1 was significantly correlated with shorter overall survival (HR 1.33, 95% CI: 1.13-1.56) and disease-free survival (HR 1.48; 95%CI: 1.10-1.97). Current evidence indicates that the level of CYFRA 21-1 in the serum could be used as an indicator for monitoring tumor status and evaluating its curative effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.